TY - JOUR
T1 - ENabling Reduction of Low-grade Inflammation in SEniors Pilot Study
T2 - Concept, Rationale, and Design
AU - ENRGISE Pilot study investigators
AU - Manini, Todd M.
AU - Anton, Stephen D.
AU - Beavers, Daniel P.
AU - Cauley, Jane A.
AU - Espeland, Mark A.
AU - Fielding, Roger A.
AU - Kritchevsky, Stephen B.
AU - Leeuwenburgh, Christiaan
AU - Lewis, Kristina H.
AU - Liu, Christine
AU - McDermott, Mary M.
AU - Miller, Michael E.
AU - Tracy, Russell P.
AU - Walston, Jeremy D.
AU - Radziszewska, Barbara
AU - Lu, Jane
AU - Stowe, Cindy
AU - Wu, Samuel
AU - Newman, Anne B.
AU - Ambrosius, Walter T.
AU - Pahor, Marco
N1 - Publisher Copyright:
© 2017, Copyright the Authors Journal compilation © 2017, The American Geriatrics Society
PY - 2017/9
Y1 - 2017/9
N2 - Objectives: To test two interventions to reduce interleukin (IL)-6 levels, an indicator of low-grade chronic inflammation and an independent risk factor for impaired mobility and slow walking speed in older adults. Design: The ENabling Reduction of low-Grade Inflammation in SEniors (ENRGISE) Pilot Study was a multicenter, double-blind, placebo-controlled randomized pilot trial of two interventions to reduce IL-6 levels. Setting: Five university-based research centers. Participants: Target enrollment was 300 men and women aged 70 and older with an average plasma IL-6 level between 2.5 and 30 pg/mL measured twice at least 1 week apart. Participants had low to moderate physical function, defined as self-reported difficulty walking one-quarter of a mile or climbing a flight of stairs and usual walk speed of less than 1 m/s on a 4-m usual-pace walk. Intervention: Participants were randomized to losartan, omega-3 fish oil (ω-3), combined losartan and ω-3, or placebo. Randomization was stratified depending on eligibility for each group. A titration schedule was implemented to reach a dose that was safe and effective for IL-6 reduction. Maximal doses were 100 mg/d for losartan and 2.8 g/d for ω-3. Measurements: IL-6, walking speed over 400 m, physical function (Short Physical Performance Battery), other inflammatory markers, safety, tolerability, frailty domains, and maximal leg strength were measured. Results: Results from the ENRGISE Pilot Study will provide recruitment yields, feasibility, medication tolerance and adherence, and preliminary data to help justify a sample size for a more definitive randomized trial. Conclusion: The ENRGISE Pilot Study will inform a larger subsequent trial that is expected to have important clinical and public health implications for the growing population of older adults with low-grade chronic inflammation and mobility limitations.
AB - Objectives: To test two interventions to reduce interleukin (IL)-6 levels, an indicator of low-grade chronic inflammation and an independent risk factor for impaired mobility and slow walking speed in older adults. Design: The ENabling Reduction of low-Grade Inflammation in SEniors (ENRGISE) Pilot Study was a multicenter, double-blind, placebo-controlled randomized pilot trial of two interventions to reduce IL-6 levels. Setting: Five university-based research centers. Participants: Target enrollment was 300 men and women aged 70 and older with an average plasma IL-6 level between 2.5 and 30 pg/mL measured twice at least 1 week apart. Participants had low to moderate physical function, defined as self-reported difficulty walking one-quarter of a mile or climbing a flight of stairs and usual walk speed of less than 1 m/s on a 4-m usual-pace walk. Intervention: Participants were randomized to losartan, omega-3 fish oil (ω-3), combined losartan and ω-3, or placebo. Randomization was stratified depending on eligibility for each group. A titration schedule was implemented to reach a dose that was safe and effective for IL-6 reduction. Maximal doses were 100 mg/d for losartan and 2.8 g/d for ω-3. Measurements: IL-6, walking speed over 400 m, physical function (Short Physical Performance Battery), other inflammatory markers, safety, tolerability, frailty domains, and maximal leg strength were measured. Results: Results from the ENRGISE Pilot Study will provide recruitment yields, feasibility, medication tolerance and adherence, and preliminary data to help justify a sample size for a more definitive randomized trial. Conclusion: The ENRGISE Pilot Study will inform a larger subsequent trial that is expected to have important clinical and public health implications for the growing population of older adults with low-grade chronic inflammation and mobility limitations.
KW - chronic inflammation
KW - immune system
KW - mobility disability
KW - physical function
UR - http://www.scopus.com/inward/record.url?scp=85029584372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029584372&partnerID=8YFLogxK
U2 - 10.1111/jgs.14965
DO - 10.1111/jgs.14965
M3 - Article
C2 - 28734043
AN - SCOPUS:85029584372
SN - 0002-8614
VL - 65
SP - 1961
EP - 1968
JO - Journal of the American Geriatrics Society
JF - Journal of the American Geriatrics Society
IS - 9
ER -